KeithDanielsKaufmanMD

Diabetes, Lipid Metabolism

Vice President, Project Leadership & Management, Merck Research Laboratories

Dr. Kaufman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1989
University of California San Francisco School of MedicineClass of 1983

PubMed

111 citations
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
Samuel S. Engel, D. E. Williams-Herman, Gregory T. Golm, R J Clay, S V Machotka
International Journal of Clinical Practice. 2010-06-01
124 citations
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, doubl...
R. Arechavaleta, Thomas Seck, Y. Chen, Karl J. Krobot, Edward A. O'Neill
Diabetes, Obesity & Metabolism. 2011-02-01
36 citations
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
D. E. Williams-Herman, Lei Xu, R. Teng, Gregory T. Golm, Jeremy Johnson
Diabetes, Obesity & Metabolism. 2012-01-01

Journal Articles

A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficienc...
Keith Kaufman, MD, Diabetes, Obesity and Metabolism